Company Overview and News
Can you imagine sharing your workspace with a little robot? Chatting freely with an AI-powered customer service agent? Or using AI tools to boost profit at your own little startup? Those are some of the visions of an artificial intelligence-powered reality being discussed at The AI Summit in London.
The futures are trading solidly higher across the board this Thursday morning as the financial world and investors continue to digest yesterday’s commentary from the Federal Reserve. As expected, the Federal Funds rate was increased by 25 basis points or ¼% to 2%, the highest level since 2008, during the financial crisis.
COF.PRG COF.PRH DB UNIT COF.WS TWX MS.PRE COF.PRP MS.PRF MS.PRG MS.PRA HPE WYND COF-D COF-C COF-F AMAT NUS KSS MS COF.PRC COF.PRD COF.PRF TTMI STLD COF-P GSKY XPO KBR COF TWC MS.PRI TEX WRB MS.PRK HMSY ROKU WTI TRI CAKE
With 1 million employees and half a dozen factories contributing 4 per cent of the country’s export value, Foxconn’s expansion symbolises China’s role as tech manufacturing powerhouse
HHPG HHPD HPE
Broadcom Inc. (AVGO - Free Report) strengthened its partnership with Hewlett Packard Enterprise Company (HPE - Free Report) in server storage. The companies will collaborate to demonstrate U.3 reference platform, SFF-TA-1001 at HPE Discover. The U.3 universal drive cage will feature Toshiba U.3 facilitated SAS, SATA and NVMe drives. U.3 technology enables SSDs (SATA, SAS and NVMe) and HDDs (SATA and SAS) to function in a single bay.
MU AVGO WDC BRCM HPE
SAN JOSE, Calif., June 12, 2018 (GLOBE NEWSWIRE) -- Broadcom Inc. (NASDAQ:AVGO) today announced it has co-sponsored and developed the approved SFF-TA-1005 Universal Backplane Management (UBM) specification with Dell EMC and Hewlett Packard Enterprise and 19 other participants, which provides a common management framework for SAS, SATA, and NVMe devices. The SFF-TA-1005 UBM specification will help to unify and standardize backplane management in the data center.
AVGO BRCM HPE
Until early March, Advanced Micro Devices, Inc. (NASDAQ:AMD) stock was in a bearish phase. Part of this had to due with the market volatility as well as worries about competitive threats from mega rivals like NVIDIA Corporation (NASDAQ:NVDA) and Intel Corporation (NASDAQ:INTC).
DVMT TCEHY CSCO AMD MSFT TCTZF NVDA INTC BIDU HPE
SAN JOSE, Calif., June 12, 2018 (GLOBE NEWSWIRE) -- Broadcom Inc. (NASDAQ:AVGO) today announced it is extending its collaboration in server storage with Hewlett Packard Enterprise (HPE). Broadcom and HPE will showcase the benefits of the SFF-TA-1001 specification commonly known as U.3 reference platform next week at HPE Discover, with a U.3 universal drive cage demonstration featuring Toshiba U.3-enabled NVMe™, SAS and SATA drives.
AVGO BRCM HPE
SAN FRANCISCO: The US$100 billion SoftBank Vision Fund has made its second-ever investment in an enterprise software company, as the massive fund broadens its portfolio beyond consumer tech firms such as Uber and DoorDash.
H AAPL HPE
SAN FRANCISCO (Reuters) - The $100 billion SoftBank Vision Fund has made its second-ever investment in an enterprise software company, as the massive fund broadens its portfolio beyond consumer tech firms such as Uber and DoorDash.
H AAPL HPE
Welcome to Seeking Alpha’s Venture Capital Deals of the Week. Follow this account and turn on the e-mail alert to receive VCDeals in your inbox on Saturday mornings.
IBM JD WDC APPN CG CRM HPE GS BABA DVMT ATHM TROW MSFT NTAP
For the second time (at least), patience has paid off when it comes to Advanced Micro Devices, Inc. (NASDAQ:AMD). AMD spent a few years hovering around $2 per share before skyrocketing in 2016. But last year, the rally faded out; by early April, AMD stock had reached a 16-month low.
TCEHY CSCO AMD TCTZF NVDA INTC HPE
10h - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
2018-06-11 - Asif
Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...
2018-06-11 - Asif
Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...
Silicon Investor Message Boards
This table lists all message boards related to HPE / Hewlett Packard Enterprise Company on message board site Silicon Investor.
|Hewlett Packard Enterprise (HPE)||North Coast Productions * Merger with ticker SHPE|
|Blue Chip Computerware (BCHPE)|
as of ET